Similarly, gefitinib and erlotinib reduced vessel formation, decreased vascular permeability, and improved tumor oxygenation in xenograft models through the inhibition of HIF-1α and the production of angiogenic factors such as VEGF-A and IL-8 by tumor cells [216,217,218]. The gene discussed is CXCL8; the disease is neoplasm.